LINC00473 modulates protein expression to promote ovarian cancer progression and overcome cisplatin resistance

The present study aimed to systematically investigate the biological role of the long non-coding RNA (lncRNA) LINC00473 in the pathogenesis and progression of ovarian cancer and to explore its potential as a novel therapeutic target for clinical translation.LINC00473 expression was specifically silenced in SK-OV-3 and A2780 ovarian cancer cell lines using small interfering RNA technology.Enhanced Cell Counting Kit-8 and Transwell invasion assays were performed to evaluate the regulatory effects of LINC00473 on malignant phenotypes (proliferation, migration, invasion and apoptosis) and chemosensitivity to cisplatin (CDDP).Western blotting was utilized to detect changes in the expression levels of apoptosis-related proteins [poly (adenosine diphosphate-ribose) polymerase (PARP) and caspase-3] and stemness/drug resistance-associated proteins [Sox2 and Yes-associated protein 1 (YAP1)].Knockdown of LINC00473 significantly inhibited ovarian cancer cell proliferation (SK-OV-3, 23.1%, P